•
LS
LSTA
Lisata Therapeutics, Inc. Common Stock
polygonPHARMACEUTICAL PREPARATIONS
--
Price Chart
Market Cap
19.05M
Volume
4.96M
52W High
$4.17
52W Low
$1.81
Open
$3.99
Prev Close
$2.16
Day Range
3.98 - 4.17
About Lisata Therapeutics, Inc. Common Stock
Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The group has one operating segment, the research and development of its investigational drug product.
Latest News
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Nathan’s Famous, Inc. (Nasdaq – NATH), Lisata Therapeutics, Inc. (Nasdaq – LSTA), Sun Country Airlines Holdings, Inc. (Nasdaq - SNCY), Ventyx Biosciences, Inc. (Nasdaq - VTYX)
GlobeNewswire Inc.•10h ago
Why Is Lisata Therapeutics Stock Gaining Today?
Benzinga•10h ago
Lisata Therapeutics and WARPNINE Announce iLSTA Trial Enrollment Completion and Provide Preliminary Data Update
GlobeNewswire Inc.•Jul 17
Lisata (LSTA) Stock Rallies More Than 30% YTD: Here's Why - Zacks Investment Research
Zacks Investment Research•Jul 16
Lisata Therapeutics Announces Full Enrollment of Pancreatic Cancer Cohort of CENDIFOX Trial
GlobeNewswire Inc.•Jun 13
Lisata Therapeutics to Participate in Upcoming June 2024 Industry and Investor Events
GlobeNewswire Inc.•May 28
Lisata Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire Inc.•May 9
Lisata Therapeutics and Qilu Pharmaceutical Announce First Patient Treated in Qilu’s Phase 2 Trial in China of LSTA1 in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
GlobeNewswire Inc.•Apr 23